|
業務類別
|
Biotechnology |
|
業務概覽
|
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191. |
| 公司地址
| 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421 |
| 電話號碼
| +1 781 761-4904 |
| 傳真號碼
| +1 339 674-6495 |
| 公司網頁
| https://www.aldeyra.com |
| 員工數量
| 8 |
| Dr. Todd C. Brady, M.D.,PhD |
Director, Chief Executive Officer and President |
美元 700.00K |
27/04/2026 |
| Mr. Michael Alfieri |
Principal Financial Officer and Principal Accounting Officer |
-- |
27/04/2026 |
|
|
| Dr. Gary M. Phillips, M.D. |
Independent Director |
27/04/2026 |
| Mr. Martin J. Joyce |
Independent Director |
20/04/2026 |
| Dr. Richard H. Douglas, PhD |
Chairman of the Board |
27/04/2026 |
| Dr. Todd C. Brady, M.D.,PhD |
Director, Chief Executive Officer and President |
27/04/2026 |
| Dr. Ben Bronstein, M.D. |
Independent Director |
27/04/2026 |
| Dr. Neal Walker, D.O. |
Independent Director |
27/04/2026 |
| Ms. Nancy Miller-Rich |
Independent Director |
27/04/2026 |
| Mr. William D. Clark |
Independent Director |
27/04/2026 |
|
|
|
|
